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Introduction
Acquired von Willebrand syndrome 
(AvWS) is a rare condition most commonly 
associated with the lymphoproliferative 
disorders, including monoclonal gammo-
pathy of undetermined significance 
(MGUS), multiple myeloma, and Walden-
ström’s macroglobulinemia.1-3 It is a 
disorder of von Willebrand factor (vWF) 
concentration, structure, or function that is 
not inherited directly but is a consequence of 
another medical disorder.4 There are 
multiple mechanisms leading to AvWS: 
autoimmune clearance or inhibition of vWF, 
increased shear-induced proteolysis of vWF, 
or increased binding of vWF to platelets or 
other cell surfaces.2,3,4 Autoantibodies 
commonly are implicated in AvWS 
associated with MGUS.1,4,5 Thus, these 
patients often do not respond to standard 
von Willebrand disease (vWD) therapy.6 
This case provided evidence that bortezomib 
may be an option for patients refractory to 
standard AvWS therapy in the setting of 
MGUS. 
 
Case Report 
A 67-year-old female without prior 
personal or family history of a bleeding 
diathesis originally presented with acute 
gastrointestinal bleeding. She subsequently 
had recurrent episodes of epistaxis and 
gastrointestinal bleeding requiring multiple 
blood transfusions. An extensive workup 
revealed the diagnosis of AvWS. She was 
not on blood thinners or any other 
medications known to cause AvWS. Her 
von Willebrand antigen at diagnosis was low 
at 3.1 units, von Willebrand ristocetin 
cofactor was 6, and factor VIII activity was 
10.7%. A short time later, she also was 
diagnosed with MGUS.  
First line treatment with desmopressin 
was initiated, but the patient had severe 
nausea and her disease had very minimal 
response. She subsequently failed therapy 
with prednisone and vWF complex. Next, 
she was given four cycles of rituximab 
therapy with only minimal response. Even 
though the patient never had a confirmed 
vWF antibody, she was next treated 
empirically with intravenous immune-
globulin (IVIG) monotherapy. She had good 
response to IVIG as evidenced by an 
increase in her vWF antigen, vWF ristocetin 
activity, and factor VIII activity.  
Over the next nine years, the patient 
received IVIG infusions for two consecutive 
days every 2½ weeks. Her episodes of 
bleeding were decreased during this nine-
year period, but she continued to have 
infrequent bleeding. She also had frequent 
headaches and nausea and another treatment 
strategy was explored.  
Based on a published case report, 
bortezomib was added to the IVIG therapy.7 
Treatment included six cycles of bortezomib 
2.5 mg on days one, four, eight, and 11 of a 
21-day cycle.7 Treatment with IVIG was 
continued during this four-month treatment 
period. During treatment, the patient had no 
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clinical bleeding and there was a remarkable 
increase in her vWF antigen, vWF activity, 
and factor VIII activity (Table 1). In 
addition, the MGUS monoclonal protein 
became undetectable. Once treatment with 
bortezomib and IVIG was stopped, 
remission was maintained for another two 
months, followed by relapse and an episode 
of gastrointestinal bleeding. The patient was 
not a candidate for additional bortezomib 
treatment due to drug-induced peripheral 
neuropathy. At that time, she resumed IVIG 
monotherapy which continued to be 
effective.  
 
Table 1. Response of vWF antigen, vWF activity, and factor VIII activity during the 10-year 
treatment course of vWD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Similar to congenital vWD, the acquired 
syndrome can cause significant morbidity 
due to bleeding.2 Unfortunately, standard 
vWD therapy is often ineffective for 
acquired von Willebrand syndrome.5 These 
patients often do not respond to 
desmopressin or vWF replacement as there 
is frequently a circulating antibody that 
rapidly destroys the new circulating vWF.5,6 
Plasma antibodies to vWF are confirmed 
infrequently, but have been demonstrated by 
plasma mixing studies and functional 
assays.4,6 In addition to antibodies, there is 
likely significant adsorption of the vWF to 
the increased circulating monoclonal cells. 
There is evidence of this occurring in 
multiple myeloma and it is possible that 
there is a similar mechanism involved in 
MGUS.8  
Desmopressin produces at least short 
term improvement in only 32% of cases.1 
Factor replacement (vWF and FVIII) is also 
part of the standard vWD treatment, but has 
proven less effective in AvWS.1,9 In patients 
who had a previous inadequate response to 
desmopressin and factor replacement, IVIG 
has some proven efficacy.1,5,9 In one study, 
33% of those who failed the first two 
therapies showed good response with IVIG.1 
Even if there is good clinical response, 
treatment with IVIG usually requires 
lifelong therapy that is both expensive and 
often difficult to tolerate. Other therapies 
such as plasmapheresis, antifibrinolytics, 
and rituximab have exhibited only marginal 
efficacy.1,10,11  
In general, there appears to be minimal 
benefit to treating MGUS unless it 
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progresses to multiple myeloma.12,13 
However, there is insufficient evidence to 
guide the management of MGUS with other 
secondary complications, such as AvWS.12 
The standard approach to MGUS may be 
unsatisfactory when the patient has 
associated AvWS.  
Bortezomib is a proteasome inhibitor 
commonly used in the treatment of multiple 
myeloma. It was shown in a prior case 
report to induce complete remission of both 
AvWS and MGUS.7 Although the response 
was only short term in our case, bortezomib 
again appeared to have the potential to treat 
AvWS concurrent with MGUS effectively.  
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